Summary
Cardinal Health, Inc. (CAH) filed an 8-K on September 27, 2004, detailing two significant events. The company announced the initiation of a formal review of its operating structure and strategic direction, aiming for cost savings in fiscal year 2005 and future growth. This review includes restructuring or exiting certain business activities, with associated costs expected across all segments. The initial phase, approved by management on September 27, 2004, involves approximately $19.0 million in termination and related benefits for employees in the Pharmaceutical Technologies and Services segment, anticipated to be incurred primarily in the first two quarters of fiscal 2005.
Key Highlights
- 1Cardinal Health is undertaking a strategic review to achieve cost savings and position for future growth.
- 2The company will incur costs related to restructuring or exiting certain business activities.
- 3An initial phase of the restructuring, focused on the Pharmaceutical Technologies and Services segment, will cost approximately $19.0 million.
- 4These restructuring costs are expected to be incurred primarily in Q1 and Q2 of fiscal year 2005.
- 5A blackout period for trading under certain employee benefit plans commenced on September 27, 2004, due to circumstances beyond the company's control.
- 6The blackout period is expected to last until the filing of the company's Form 10-K, targeted for late October 2004.
- 7The company is complying with Sarbanes-Oxley Act requirements regarding the employee benefit plan blackout period.
Frequently Asked Questions
The purpose of the strategic review is to examine aspects of Cardinal Health's current operating structure and future strategic directions, with the overarching goals of achieving cost savings in fiscal year 2005 and positioning the company for future growth.
The company is unable to provide a precise total estimate due to the early stage of evaluation. However, the first phase, approved on September 27, 2004, involves approximately $19.0 million in one-time termination and related benefits for employees in the Pharmaceutical Technologies and Services segment. These costs are expected to be incurred primarily in the first and second quarters of fiscal 2005.
A blackout period was imposed on certain employee benefit plans starting September 27, 2004. This is due to circumstances beyond the company's reasonable control and is required by Section 306(a) of the Sarbanes-Oxley Act of 2002. The blackout period is expected to last until the company files its Form 10-K, anticipated by late October 2004.
More specific financial details and estimates for the restructuring costs are not yet available as the evaluation is in its early stages. Investors can anticipate further information as the company files its Form 10-K, which is expected by late October 2004, and through subsequent SEC filings and press releases.